ALEMTUZUMAB PROTOKOLÜ

Kaynaklar:

1- Gómez-Almaguer D, Ruiz-Arguelles GJ, del Carmen Tarin-Arzaga L, et al. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2008;14(1):10–15. 

2- Morris PJ, Russell NK. Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation. 2006;81(10):1361–1367.

3- Dick AD, Meyer P, James T, et al. Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol. 2000;84(1):107–109.

4- Risitano AM, Selleri C, Serio B, et al. Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br J Haematol. 2010;148(5):791–796.

5- Scheinberg P, Nunez O, Weinstein B, et al. Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia Blood. 2012; 119(2): 345–354.

6- Lundin et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath) as first line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768-73. 

7- Keating et al. Therapeutic role of alemtuzumab (Campath IH) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-61.